Pnc Financial Services Group, Inc. Supernus Pharmaceuticals, Inc. Transaction History

Pnc Financial Services Group, Inc.

  • $156 Billion
  • Q3 2024

A detailed history of Pnc Financial Services Group, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 15,733 shares of SUPN stock, worth $568,590. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,733
Previous 17,110 8.05%
Holding current value
$568,590
Previous $457,000 7.22%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
SELL
$25.77 - $35.16 $35,485 - $48,415
-1,377 Reduced 8.05%
15,733 $490,000
Q2 2024

Aug 09, 2024
SELL
$25.99 - $33.85 $74,669 - $97,251
-2,873 Reduced 14.38%
17,110 $457,000
Q1 2024

May 10, 2024
SELL
$27.11 - $35.17 $59,777 - $77,549
-2,205 Reduced 9.94%
19,983 $681,000
Q4 2023

Feb 09, 2024
BUY
$22.72 - $29.68 $5,589 - $7,301
246 Added 1.12%
22,188 $642,000
Q3 2023

Nov 13, 2023
SELL
$27.57 - $32.91 $95,585 - $114,098
-3,467 Reduced 13.64%
21,942 $604,000
Q2 2023

Aug 11, 2023
SELL
$29.91 - $38.73 $5,982 - $7,745
-200 Reduced 0.78%
25,409 $763,000
Q1 2023

May 15, 2023
SELL
$34.93 - $42.03 $1,746 - $2,101
-50 Reduced 0.19%
25,609 $927,000
Q4 2022

Feb 10, 2023
SELL
$31.09 - $37.88 $165,616 - $201,786
-5,327 Reduced 17.19%
25,659 $915,000
Q3 2022

Nov 10, 2022
SELL
$28.79 - $35.41 $35,872 - $44,120
-1,246 Reduced 3.87%
30,986 $1.05 Million
Q2 2022

Aug 12, 2022
BUY
$25.33 - $34.25 $25,380 - $34,318
1,002 Added 3.21%
32,232 $932,000
Q1 2022

May 12, 2022
SELL
$28.51 - $32.9 $30,192 - $34,841
-1,059 Reduced 3.28%
31,230 $1.01 Million
Q4 2021

Feb 11, 2022
BUY
$26.37 - $34.22 $216,392 - $280,809
8,206 Added 34.07%
32,289 $941,000
Q3 2021

Nov 05, 2021
BUY
$23.54 - $31.39 $46,703 - $62,277
1,984 Added 8.98%
24,083 $642,000
Q2 2021

Aug 06, 2021
BUY
$26.72 - $33.19 $59,371 - $73,748
2,222 Added 11.18%
22,099 $680,000
Q1 2021

May 07, 2021
BUY
$24.15 - $31.45 $266,954 - $347,648
11,054 Added 125.29%
19,877 $520,000
Q4 2020

Feb 12, 2021
BUY
$17.7 - $25.81 $12,000 - $17,499
678 Added 8.32%
8,823 $221,000
Q3 2020

Nov 06, 2020
BUY
$20.2 - $25.05 $32,421 - $40,205
1,605 Added 24.54%
8,145 $169,000
Q2 2020

Aug 07, 2020
BUY
$17.09 - $24.89 $79,895 - $116,360
4,675 Added 250.67%
6,540 $155,000
Q1 2020

May 08, 2020
SELL
$14.45 - $24.69 $13,915 - $23,776
-963 Reduced 34.05%
1,865 $33,000
Q4 2019

Feb 07, 2020
SELL
$19.93 - $29.13 $343,194 - $501,618
-17,220 Reduced 85.89%
2,828 $67,000
Q3 2019

Nov 08, 2019
SELL
$25.47 - $33.37 $1.85 Million - $2.42 Million
-72,541 Reduced 78.35%
20,048 $550,000
Q2 2019

Aug 09, 2019
SELL
$29.96 - $38.87 $1.52 Million - $1.97 Million
-50,765 Reduced 35.41%
92,589 $0
Q1 2019

May 10, 2019
SELL
$32.77 - $41.99 $1.54 Million - $1.98 Million
-47,087 Reduced 24.73%
143,354 $0
Q4 2018

Feb 08, 2019
SELL
$30.84 - $49.51 $475,367 - $763,147
-15,414 Reduced 7.49%
190,441 $6.33 Million
Q3 2018

Nov 09, 2018
SELL
$42.7 - $56.55 $114,521 - $151,667
-2,682 Reduced 1.29%
205,855 $0
Q2 2018

Aug 10, 2018
SELL
$44.1 - $59.85 $70,736 - $95,999
-1,604 Reduced 0.76%
208,537 $0
Q1 2018

May 11, 2018
SELL
$37.15 - $46.9 $68,950 - $87,046
-1,856 Reduced 0.88%
210,141 $0
Q4 2017

Feb 09, 2018
SELL
$36.4 - $42.6 $467,521 - $547,154
-12,844 Reduced 5.71%
211,997 $0
Q3 2017

Nov 13, 2017
BUY
$36.75 - $49.65 $8.26 Million - $11.2 Million
224,841
224,841 $0

Others Institutions Holding SUPN

# of Institutions
282
Shares Held
60.9M
Call Options Held
27.7K
Put Options Held
11.3K
View Full List

About SUPERNUS PHARMACEUTICALS, INC.

SUPN Quotes by TradingView
  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.93B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email